Apoptosis in raloxifene-treated postmenopausal women

Cell Biology International

Volumn 31, Issue 3, 2007, Pages 289-292

  Biri, A ^a   Yurtcu, E ^b   Ciftci, B ^a   Korucuoǧlu, Ü ^a   Ilhan, M N ^a   Ergun, M A ^a   Gursoy, R ^a   Biberoglu, K ^a  

^a GAZI UNIVERSITY   (Turkey)

^b BASKENT UNIVERSITY   (Turkey)

Author keywords

Apoptosis; Lymphocytes; Raloxifene

Indexed keywords

DNA FRAGMENT; RALOXIFENE;

ADULT; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; IMMUNE SYSTEM; OSTEOPOROSIS; PERIPHERAL LYMPHOCYTE; POSTMENOPAUSE; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

AGED; APOPTOSIS; FEMALE; HUMANS; LYMPHOCYTES; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TREATMENT OUTCOME;

EID: 33847072150     PISSN: 10656995     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cellbi.2006.11.004     Document Type: Article

References (17)

1. Bryant H.U., Wilson P.K., Adrian M.D., Cole H.W., Philips D.L., Dodge J.A., et al. Selective estrogen receptor modulators: pharmacological profile in the rat uterus. J Soc Gynecol Invest 3 (1996) 152A
2. Bryant H.U., Glasebrook A.L., Yang N.N., and Sato M. An estrogen receptor basis for raloxifene action in bone. J Steroid Biochem Mol Biol 69 (1999) 37-44
3. Delmas P.D., BJarnason N.H., Mitlak B.H., Ravoux A.-C., Shah A.S., Huster W.J., et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337 (1997) 1641-1647
4. Dowsett M., Bundred N.J., Decensi A., Sainsbury R.C., Lu Y., Hills M.J., et al. Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients. Cancer Epidemiol Biomarkers Prev 10 9 (2001) 961-966
5. Ergun U., Yurtcu E., and Ergun M.A. Protective effect of ginkgo biloba against gossypol-induced apoptosis in human lymphocytes. Cell Biol Int 29 8 (2005) 717-720
6. Erlandsson M.C., Gomori E., Taube M., and Carlsten H. Effects of raloxifene, a selective estrogen receptor modulator, on thymus, T cell reactivity, and inflammation in mice. Cell Immunol 205 2 (2000) 103-109
7. Franke T.F., and Cantley L.C. Apoptosis. A bad kinase makes good. Nature 390 (1997) 116-117
8. Garcia-Moreno C., Catalan M.P., Ortiz A., Alvarez L., and De la Piedra C. Modulation of survival in osteoblasts from postmenopausal women. Bone 35 1 (2004) 170-177
9. Gong J., Traganos F., and Darzynkiewicz Z. A selective procedure for DNA extraction from apoptotic cells applicable for gel electrophoresis and flow cytometry. Anal Biochem 218 (1994) 314-319
10. Katznellenbongen B.S., and Katznellenbongen J.A. Defining the 'S' in SERM's. Science 295 (2002) 2380-2381
11. Kim H.T., Kim B.C., Kim I.Y., Mamura M., Seong D.H., Jang J.J., et al. Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis through cleavage of BAD in TSU-PR1 human cancer cells. J Biol Chem 277 36 (2002) 32510-32515
12. Kim I.Y., Kim B.C., Seong do H., Lee D.K., Seo J.M., Hong Y.J., et al. Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines. Cancer Res 62 18 (2002) 5365-5369
13. Kousteni S., Bellido T., Plotkin L.I., O'Brien C.A., Bodenner D.L., Han L., et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 104 (2001) 719-730
14. Mori-Abe A., Tsutsumi S., Takahashi K., Toya M., Yoshida M., Du B., et al. Estrogen and raloxifene induce apoptosis by activating p38 mitogen-activated protein kinase cascade in synthetic vascular smooth muscle cells. J Endocrinol 178 3 (2003) 417-426
15. Nechushtan A., Smith C.L., Lamensdorf I., Yoon S.-H., and Youle R.-J. Bax and Bak coalesce into novel mitochondria-associated clusters during apoptosis. J Cell Biol 153 (2001) 1265-1276
16. Olivier S., Fillet M., Malaise M., Piette J., Bours V., Merville M.P., et al. Sodium nitroprusside-induced osteoblast apoptosis is mediated by long chain ceramide and is decreased by raloxifene. Biochem Pharmacol 69 6 (2005) 891-901
17. Palomba S., Orio F., Russo T., Falbo A., Tolino A., Lombardi G., et al. Antiproliferative and proapoptotic effects of raloxifene on uterine leiomyomas in postmenopausal women. Fertil Steril 84 1 (2005) 154-161